Talquetamab: all 30 studies that test it
Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingNCT07887984Phase 2/3
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingNCT07740486Phase 3
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingNCT07720843Phase 1
- Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingNCT07657312Phase 2
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
- Talquetamab in Patients With Refractory Generalized Myasthenia GravisNot yet recruitingNCT07499323Not applicable
- Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.RecruitingNCT07107529Phase 2
- Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07093554Phase 1
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaRecruitingNCT07032714Phase 1
- MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple MyelomaNot yet recruitingNCT07029776Phase 2
- Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma PatientsRecruitingNCT06505369Phase 2
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingNCT06500884Phase 2
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaRecruitingNCT06461988Phase 2
- Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaRecruitingNCT06348108Phase 1
- Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)RecruitingNCT06100237Phase 2
- A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell TherapyRecruitingNCT06066346Phase 2
- Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingNCT05972135Phase 2
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Phase 3
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Phase 2
- External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary DiseaseSuspendedNCT06572605Phase 1/2
- A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaActive, not recruitingNCT06550895Phase 2
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Phase 3
- Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaActive, not recruitingNCT05849610Phase 2
- A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple MyelomaWithdrawnNCT05461209Phase 3
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Phase 3
- A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05338775Phase 1
- A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT04773522Phase 1
- A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04586426Phase 1/2
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03399799Phase 1